IASO BIOTHERAPEUTICS

iaso-biotherapeutics-logo

IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

#SimilarOrganizations #People #Financial #Event #Website #More

IASO BIOTHERAPEUTICS

Industry:
Biotechnology Pharmaceutical

Founded:
2017-01-01

Address:
Nanjing, Jiangsu, China

Country:
China

Website Url:
http://www.iasobio.com

Total Employee:
251+

Status:
Active

Contact:
025-58287610

Email Addresses:
[email protected]

Total Funding:
168 M USD

Technology used in webpage:
SPF Apache Euro Microsoft Azure DNS PHP Apache 2.4 OpenSSL GlobalSign HiChina DNS Win32 Header


Similar Organizations

aura-biosciences-logo

Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

dunad-therapeutics-logo

Dunad Therapeutics

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

immutep-logo

Immutep

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

mrm-health-nv-logo

MRM Health NV

MRM Health NV is a biopharmaceutical company focused on the discovery and development of therapeutics based on the human microbiome.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

sirnaomics-logo

Sirnaomics

Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.

wehand-logo

WeHand

WeHand is a biopharmaceutical company focusing on the development of hypoglycemic drugs.

Current Employees Featured

wen-wang_image

Wen Wang
Wen Wang CEO & CMO @ IASO Biotherapeutics
CEO & CMO

brian-k-hall_image

Brian K. Hall
Brian K. Hall Co-Founder & Executive Vice President @ IASO Biotherapeutics
Co-Founder & Executive Vice President

david-he_image

David HE
David HE Chief Technology Officer and Executive Vice President @ IASO Biotherapeutics
Chief Technology Officer and Executive Vice President
2021-06-01

biao-zheng_image

Biao Zheng
Biao Zheng Chief Scientific Officer @ IASO Biotherapeutics
Chief Scientific Officer
2020-09-01

alan-fu_image

Alan Fu
Alan Fu Chief Financial Officer (CFO) @ IASO Biotherapeutics
Chief Financial Officer (CFO)
2021-10-01

Founder


brian-k-hall_image

Brian K. Hall

Investors List

co-stone-capital_image

Co-Stone Venture Capital

Co-Stone Venture Capital investment in Series C - IASO Biotherapeutics

everbright_image

Everbright

Everbright investment in Series C - IASO Biotherapeutics

ccb-international_image

CCB International

CCB International investment in Series C - IASO Biotherapeutics

plaisance-capital_image

Plaisance Capital

Plaisance Capital investment in Series C - IASO Biotherapeutics

cdh-investments_image

CDH Investments

CDH Investments investment in Series C - IASO Biotherapeutics

gl-ventures_image

GL Ventures

GL Ventures investment in Series C - IASO Biotherapeutics

cncb-capital_image

CNCB Capital

CNCB Capital investment in Series C - IASO Biotherapeutics

hillhouse-capital_image

Hillhouse Capital Group

Hillhouse Capital Group investment in Series B - IASO Biotherapeutics

Key Employee Changes

Date New article
2021-10-19 IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer

Official Site Inspections

http://www.iasobio.com

  • Host name: 120.133.2.80
  • IP address: 120.133.2.80
  • Location: China
  • Latitude: 34.7725
  • Longitude: 113.7266
  • Timezone: Asia/Shanghai

Loading ...

More informations about "IASO Biotherapeutics"

Overview / ABOUT IASO / IASO,IASO Bio,IASO …

IASO,IASO Bio,IASO Biotherapeutics,IASO Biopharma,CT103A, CAR-T, cell therapy,dual-targeted CAR-TSee details»

IASO BioTherapeutics(驯鹿生物) - LinkedIn

IASO BioTherapeutics(驯鹿生物) | 1,638 followers on LinkedIn. Transforming innovation into life-changing therapies | IASO Bio is a clinical-stage biopharmaceutical company engaged in the ...See details»

IASO Biotherapeutics - Crunchbase Company Profile

IASO Biotherapeutics may be growing as it has recently achieved a significant regulatory milestone and secured substantial venture funding. The company, …See details»

Nanjing IASO Biotherapeutics Co., Ltd. - Drug pipelines ... - Patsnap

Cn.iasobio.com. Startups | Holding Company | Subsidiary Company | 2017 | Jiangsu Sheng, China | 100-250 | cn.iasobio.com. Last update 08 Mar 2025. Overview. Pipeline. ... The statistics for …See details»

Next Generation Vaccines - Iaso Therapeutics

Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, …See details»

IASO Biotherapeutics - Overview, News & Similar companies

Apr 3, 2024 IASO Biotherapeutics contact info: Phone number: +86 2558287610 Website: www.iasobio.com What does IASO Biotherapeutics do? Founded in 2017, IASO BIO is a …See details»

IASO BIO - 2025 Company Profile, Funding & Competitors - Tracxn

4 days ago IASO BIO has raised a total funding of $178M over 3 rounds. Its first funding round was on Mar 23, 2020. Its latest funding round was a Series C round on Jan 18, 2023 for an …See details»

驯鹿生物

驯鹿生物,驯鹿医药,驯鹿医疗,驯鹿技术,驯鹿科技,上海驯鹿,南京驯鹿,IASO BIO,IASO Biothrapeutics,驯鹿CAR-T细胞治疗,多发性骨髓瘤CAR-T,全人源双靶点CAR-TSee details»

IASO Bio 2025 Company Profile: Valuation, Funding

IASO Bio General Information Description. Developer of cellular innovative drugs designed for cancer biotherapeutics. The company's cell-therapy products aim to treat symptoms of hematological tumors, solid tumors and virus associated …See details»

Nanjing IASO Biotherapeutics Co., Ltd. - synapse.zhihuiya.com

4 days ago 了解Nanjing IASO Biotherapeutics Co., Ltd. (南京驯鹿生物技术股份有限公司)公司的药物管线,治疗领域,技术平台,以及它的23项临床试验, 798篇新闻和7篇文献,疾病领域:肿 …See details»

IASO Biotherapeutics Secures $108 Million Series C Funding to …

September 16, 2021, PLEASANTON, Calif. & NANJING, SHANGHAI, China – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on …See details»

IASO Biotherapeutics - VentureRadar

Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»

Management Team / ABOUT IASO / IASO,IASO Bio,IASO …

IASO,IASO Bio,IASO Biotherapeutics,IASO Biopharma,CT103A, CAR-T, cell therapy,dual-targeted CAR-TSee details»

IASO Bio and Innovent Enhance Strategic Collaboration in Cell …

Jul 5, 2024 NANJING, SHANGHAI, CHINA, and SAN JOSE, CA., U.S., July 5, 2024 – IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, …See details»

Growth & Development / CAREERS / IASO,IASO Bio,IASO …

We believe that both professionals and leaders play a vital role in driving business development, therefore, IASO offers dual career path of Professional and Management opportunities for …See details»

IASO BIO Announces New Development Partnership with Umoja …

SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 03, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged …See details»

IASO BIO Announces New Development Partnership with Umoja …

Jan 4, 2024 SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 04, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical …See details»

IASO,IASO Bio,IASO Biotherapeutics,IASO …

IASO,IASO Bio,IASO Biotherapeutics,IASO Biopharma,CT103A, CAR-T, cell therapy,dual-targeted CAR-TSee details»

IASO Bio Receives FDA Approval of IND Application for IASO-782 …

Jun 16, 2023 The second product of IASO to receive IND approval from the FDA . SHANGHAI, NANJING, CHINA, AND SAN JOSE , Calif., June 16, 2023 - IASO Biotechnology (“IASO Bio”), …See details»

Management Team / ABOUT IASO / IASO,IASO Bio,IASO …

Dr. Jie Chen is the Chief Medical Officer at IASO Bio. He has 14 years of experience as an oncologist and over 20 years in the industry. Before joining IASO Bio, Dr. Chen was the Chief …See details»

linkstock.net © 2022. All rights reserved